Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Recombinant Adeno-associated virus vectors (rAAV) are widely used for gene delivery and multiple naturally occurring serotypes have been harnessed to target cells in different tissues and organs including the brain. Here, we provide a detailed and quantitative analysis of the transduction profiles of rAAV vectors based on six of the most commonly used serotypes (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9) that allows systematic comparison and selection of the optimal vector for a specific application. In our studies we observed marked differences among serotypes in the efficiency to transduce three different brain regions namely the striatum, hippocampus and neocortex of the mouse. Despite the fact that the analyzed serotypes have the general ability to transduce all major cell types in the brain (neurons, microglia, astrocytes and oligodendrocytes), the expression level of a reporter gene driven from a ubiquitous promoter varies significantly for specific cell type / serotype combinations. For example, rAAV8 is particularly efficient to drive transgene expression in astrocytes while rAAV9 appears well suited for the transduction of cortical neurons. Interestingly, we demonstrate selective retrograde transport of rAAV5 along axons projecting from the ventral part of the entorhinal cortex to the dentate gyrus. Furthermore, we show that self-complementing rAAV can be used to significantly decrease the time required for the onset of transgene expression in the mouse brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“AAV5 transduces only granular cells”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“AAV2 is restricted to pyramidal and granular cells”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They express the transgene within days or weeks and can reach full expression levels after 4-6 weeks in vivo [20,21].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the promoter was cytomegalovirus (CMV), AAV9 has robust tropism for neurons and displays high expression levels in the hippocampus (Aschauer et al., 2013).”
From Hippocampal TMEM55B overexpression in the 5XFAD mouse model of Alzheimer's disease (2024) · cites this paper as Aschauer et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340 · cited 1×
“We choose the hippocampus as this is an intensely studied brain region for its role in memory formation and spatial navigation [20], the striatum for its role in the coordination of movements and neurological diseases such as Parkinson’s disease [21,22] and finally the neocortex as the part of the brain specific to ma…”
Genome-wide atlas of gene expression in the adult mouse brain
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., et al. (2007) · Nature · doi:10.1038/nature05453 · Cited by 5,572 · cited 1×
“However, in situ expression data does not indicate selective expression of PDGFR alpha or beta in the entorhinal cortex that could explain specific retrograde labeling of entorhinal neurons in a simple manner [67].”
BackgroundInterneurons of the neocortical inhibitory system
Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., & Wu, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1519 · Cited by 2,954 · cited 1×
“We chose gamma-aminobutyric acid (GABA) as a marker for the major population of inhibitory neurons in the central brain [27], oligodendrocyte transcription factor 2 (Olig2) as a marker for oligodendrocytes [28], ionized calcium-binding adapter molecule 1 (Iba1) as a marker for microglia [29] and glial fibrillary acidi…”
MethodA resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex
Taniguchi, H., He, M., Wu, P., Kim, S., Paik, R., Sugino, K., Kvitsani, D., Fu, Y., Lu, J., Lin, Y., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.026 · Cited by 1,828 · cited 2×
“To determine what population of long-range projecting neurons is selectively labeled by AAV5 we performed injections of rAAV5 in a transgenic mouse strain in which GABA-ergic interneurons are labeled by the red fluorescent reporter protein tdTomato [26,50].”
BackgroundMethodLearning and Memory Functions of the Basal Ganglia
Packard, M. G., & Knowlton, B. J. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142937 · Cited by 1,717 · cited 1×
“We choose the hippocampus as this is an intensely studied brain region for its role in memory formation and spatial navigation [20], the striatum for its role in the coordination of movements and neurological diseases such as Parkinson’s disease [21,22] and finally the neocortex as the part of the brain specific to ma…”
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 3×
“Indeed, significant differences in transduction efficacy of various serotypes for particular tissues and cell types have been described [11,12,16-19].”
BackgroundAmygdala circuitry mediating reversible and bidirectional control of anxiety
Tye, K. M., Prakash, R., Kim, S.-Y., Fenno, L. E., Grosenick, L., Zarabi, H., Thompson, K. R., Gradinaru, V., Ramakrishnan, C., & Deisseroth, K. (2011) · Nature · doi:10.1038/nature09820 · Cited by 1,289 · cited 1×
“In recent years many studies have taken advantage of recombinant viral vectors derived from Adeno-associated virus (AAV) as a gene delivery tool [3-5].”
BackgroundInduction of neurogenesis in the neocortex of adult mice
Magavi, S. S., Leavitt, B. R., & Macklis, J. D. (2000) · Nature · doi:10.1038/35016083 · Cited by 1,216 · cited 1×
“In addition, all sections were stained with the pan-neuronal marker neuronal nuclei (NeuN) [31] and the DNA stain DAPI that highlights nuclei.”
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs
Olson, J. K., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3916 · Cited by 1,215 · cited 1×
“This stimulus is known to induce an acute inflammatory response [36] and shows that our protocol to detect microglia is sensitive to tissue undergoing an immune reaction and that this reaction is limited locally to one hemisphere (Figure 4).”
BackgroundMonosynaptic Restriction of Transsynaptic Tracing from Single, Genetically Targeted Neurons
Wickersham, I. R., Lyon, D. C., Barnard, R. J. O., Mori, T., Finke, S., Conzelmann, K.-K., Young, J. A. T., & Callaway, E. M. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.033 · Cited by 1,187
Cited by
Ventromedial hypothalamic neurons control a defensive emotion state
Kunwar, P. S., Zelikowsky, M., Remedios, R., Cai, H., Yilmaz, M., Meister, M., & Anderson, D. J. (2015) · eLife · doi:10.7554/elife.06633 · Cited by 1,101
“To do so, we used a more penetrant and highly expressing viral serotype, AAV5, for delivery of ChR2 to SF1+ neurons (Aschauer et al., 2013).”
Zingg, B., Chou, X.-L., Zhang, Z.-G., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 752
Foster, E., Wildner, H., Tudeau, L., Haueter, S., Ralvenius, W. T., Jegen, M., Johannssen, H., Hösli, L., Haenraets, K., Ghanem, A., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.028 · Cited by 356
“Serotype 1was chosen because retrograde infection of central neurons through axons or axon terminals by this serotype is generally negligible (Aschauer et al., 2013; Chamberlin et al., 1998).”
BackgroundWatakabe, A., Ohtsuka, M., Kinoshita, M., Takaji, M., Isa, K., Mizukami, H., Ozawa, K., Isa, T., & Yamamori, T. (2015) · Neuroscience Research · doi:10.1016/j.neures.2014.09.002 · Cited by 303
Hippocampal oxytocin receptors are necessary for discrimination of social stimuli
Raam, T., McAvoy, K. M., Besnard, A., Veenema, A. H., & Sahay, A. (2017) · Nature Communications · doi:10.1038/s41467-017-02173-0 · Cited by 292
DREADDS: Use and application in behavioral neuroscience.
Smith, K. S., Bucci, D. J., Luikart, B. W., & Mahler, S. V. (2016) · Behavioral Neuroscience · doi:10.1037/bne0000135 · Cited by 239
Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery
Bors, L. A., & Erdő, F. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87010006 · Cited by 252
“Furthermore, the different serotypes have preferences in cell types: AAV4 primarily targets ependymal cells [230], AAV8 tranduces astrocytes, microglia, and oligodendrocytes the most, and AAV9 had the greatest tropism for neurons [226].”
BackgroundRegulation and function of SOX9 during cartilage development and regeneration
Song, H., & Park, K.-H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.04.008 · Cited by 246
Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation
Haery, L., Deverman, B. E., Matho, K. S., Cetin, A., Woodard, K., Cepko, C., Guerin, K. I., Rego, M. A., Ersing, I., Bachle, S. M., et al. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00093 · Cited by 211
Jüttner, J., Szabo, A., Gross-Scherf, B., Morikawa, R. K., Rompani, S. B., Hantz, P., Szikra, T., Esposti, F., Cowan, C. S., Bharioke, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0431-2 · Cited by 218
“We used four different AAV capsids to adapt to different species and infection routes: AAV8 (Allocca et al., 2007), AAV9 (Allocca et al., 2007; Lebherz et al., 2008), and AAV8BP2 (Cronin et al., 2014) for adult mouse retina; AAV8BP2 for adult non-human primate, and human retina; AAV9 (Aschauer et al., 2013) for adult…”
BackgroundNishiyama, J., Mikuni, T., & Yasuda, R. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.004 · Cited by 215
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Synaptic Specificity and Application of Anterograde Transsynaptic AAV for Probing Neural Circuitry
Zingg, B., Peng, B., Huang, J., Tao, H. W., & Zhang, L. I. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.2158-19.2020 · Cited by 186
“Given that AAV1 is also capable of retrograde transport (Aschauer et al., 2013; Rothermel et al., 2013; Masamizu et al., 2014; Tervo et al., 2016; Zingg et al., 2017; Fig.”
BackgroundMethodFenno, L. E., Ramakrishnan, C., Kim, Y. S., Evans, K. E., Lo, M., Vesuna, S., Inoue, M., Cheung, K. Y. M., Yuen, E., Pichamoorthy, N., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.003 · Cited by 176
“The identity of cells infected by a particular AAV is affected by AAV serotype (Aschauer et al., 2013; Burger et al., 2004; Davidson et al., 2000), developmental time point (Chakrabarty et al.”
BackgroundBIN1 favors the spreading of Tau via extracellular vesicles
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45676-0 · Cited by 171
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 176
“10 are primarily neurotropic in their transduction capacity,(68) whereas AAV2 is restricted to pyramidal and granular cells,(69) AAV4 is astrocyte and ependymal cell specific(70), and AAV5 transduces only granular cells.(69) Of these AAV serotypes, the most commonly used for clinical trials to date are AAV5, AAV9, and…”
BackgroundHammond, S. L., Leek, A. N., Richman, E. H., & Tjalkens, R. B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188830 · Cited by 160
“Based on morphological colocalization studies, we noted a lack of co-localization of GFP with IBA1 cells using any serotype (see Fig F in S1 File)This is consistent with other reports using these AAV vectors, which identified oligodendrocytes as an additional cell type transduced by these vectors rather than microglia…”
BackgroundMethodResultInfluentialEkman, F. K., Ojala, D. S., Adil, M. M., Lopez, P. A., Schaffer, D. V., & Gaj, T. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.009 · Cited by 159
“…we hypothesized that CRISPR-Cas9 could be used to disrupt the expression of the HTT gene following its in vivo delivery using an AAV vector, a clinically promising engineered gene delivery vehicle 35,36 capable of transducing various substructures within the brain, 37 including the striatum.”
MethodPutting a finishing touch on GECIs
Rose, T., Goltstein, P. M., Portugues, R., & Griesbeck, O. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00088 · Cited by 152
Nassi, J. J., Cepko, C. L., Born, R. T., & Beier, K. T. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00080 · Cited by 155
“…some of the modern neuroanatomical strategies permitted by viruses and their Frontiers in Neuroanatomy | www.frontiersin.org 3 July 2015 | Volume 9 | Article 80 genetically altered cousins, ending with a discussion of possible directions for further development of these powerful biological tools.”
BackgroundLights, fiber, action! A primer on in vivo fiber photometry
Simpson, E. H., Akam, T., Patriarchi, T., Blanco-Pozo, M., Burgeno, L. M., Mohebi, A., Cragg, S. J., & Walton, M. E. (2023) · Neuron · doi:10.1016/j.neuron.2023.11.016 · Cited by 189
“81,88 One tool available to help identify an appropriate serotype, promoter, and titer for AAV vectors for a specific experiment is the AAV Data Hub hosted by Addgene (a popular source for viral vectors).”
Two-photon calcium imaging of neuronal activity
Grienberger, C., Giovannucci, A., Zeiger, W., & Portera‐Cailliau, C. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00147-1 · Cited by 188
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Regulation and function of neurogenesis in the adult mammalian hypothalamus
Yoo, S., & Blackshaw, S. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.001 · Cited by 168
Liguore, W. A., Domire, J. S., Button, D., Wang, Y., Dufour, B. D., Srinivasan, S., & McBride, J. L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.017 · Cited by 150
A comprehensive thalamocortical projection map at the mesoscopic level
Hunnicutt, B. J., Long, B. R., Kusefoglu, D., Gertz, K. J., Zhong, H., & Mao, T. (2014) · Nature Neuroscience · doi:10.1038/nn.3780 · Cited by 150
Campbell, E. J., & Marchant, N. J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14146 · Cited by 140
“The AAV serotype 2/5 has also been shown to have retrograde tropism (Aschauer et al., 2013).”
BackgroundAdeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
“Many serotypes broadly transduce neurons and glia in the brain after direct intra-parenchymal injection (Aschauer et al. 2013, Watakabe et al. 2015).”
BackgroundMonitoring activity in neural circuits with genetically encoded indicators
Broussard, G. J., Liang, R., & Tian, L. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00097 · Cited by 142
“In addition, rAAV9 is well suited for the transduction of cortical neurons (Cearley and Wolfe, 2006), while rAAV8 is particularly efficient in labeling astrocytes (Aschauer et al., 2013).”
BackgroundMetachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches
Shaimardanova, A. A., Chulpanova, D. S., Solovyeva, V. V., Mullagulova, A. I., Kitaeva, K. V., Allegrucci, C., & Rizvanov, A. A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.576221 · Cited by 157
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 143
Adeno-Associated Viral Vectors in Neuroscience Research
Haggerty, D. L., Grecco, G. G., Reeves, K. C., & Atwood, B. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.012 · Cited by 118
Retronasal Odor Perception Requires Taste Cortex, but Orthonasal Does Not
Blankenship, M. L., Grigorova, M., Katz, D. B., & Maier, J. X. (2018) · Current Biology · doi:10.1016/j.cub.2018.11.011 · Cited by 143
Griciuc, A., Federico, A. N., Natasan, J., Forte, A. M., McGinty, D., Nguyen, H., Volak, A., LeRoy, S., Gandhi, S., Lerner, E. P., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa179 · Cited by 121
“As AAV9 (and exo-AAV) primarily transduce neurons and astrocytes following direct injection into the brain (22) with somemicroglia transduction reported (32), it is likely only a small number of microglia were directly transduced by exo-AAV9-miR.”
BackgroundMassively parallel cis-regulatory analysis in the mammalian central nervous system
Shen, S. Q., Myers, C. A., Hughes, A. E. O., Byrne, L. C., Flannery, J. G., & Corbo, J. C. (2016) · Genome Research · doi:10.1101/gr.193789.115 · Cited by 126
“AAV9 is a serotype that exhibits broad tissue tropism, and its tyrosine-mu-tated derivative AAV9(2YF) transduces neurons of the CNS with high efficiency and minimal host-mediated degradation of viral particles (Zhong et al. 2008; Zincarelli et al. 2008; Dalkara et al. 2012; Aschauer et al. 2013).”
Chen, Y.-H., Wu, J., Hu, N.-Y., Zhuang, J.-P., Li, W., Zhang, S.-R., Li, X.-W., Yang, J., & Gao, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145692 · Cited by 139
Nieuwenhuis, B., Haenzi, B., Hilton, S., Carnicer-Lombarte, A., Hobo, B., Verhaagen, J., & Fawcett, J. W. (2021) · Gene Therapy · doi:10.1038/s41434-020-0169-1 · Cited by 114
McLean, J. R., Smith, G. A., Rocha, E. M., Hayes, M. A., Beagan, J. A., Hallett, P. J., & Isacson, O. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.044 · Cited by 110
Stanimirovic, D. B., Sandhu, J. K., & Costain, W. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0309-y · Cited by 105
Chen, X., Wolfe, D. A., Bindu, D. S., Zhang, M., Taskin, N., Goertsen, D., Shay, T. F., Sullivan, E. E., Huang, S., Kumar, S. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38582-7 · Cited by 117
Emerging Gene Therapies for Genetic Hearing Loss
Ahmed, H., Shubina-Oleinik, O., & Holt, J. R. (2017) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-017-0634-8 · Cited by 110
“…improvement of tropism and efficiency of transduction (Rabinowitz and Samulski 2000; Zincarelli et al. 2008; Yu et al. 2009; Geguchadze et al. 2012; Aschauer et al. 2013; Sallach et al. 2014; Zinn et al. 2015; Castle et al. 2016; Mao et al. 2016; Marsic and Zolotukhin 2016; Payne et al. 2016;…”
BackgroundAlhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“However, there is no convincing evidence that AAV1 serotypes are transsynaptically transfecting distant cell types (Aschauer et al, 2013; Castle et al, 2014).”
BackgroundLewandowski, G. A., & Steward, O. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1996-14.2014 · Cited by 102
A descending dopamine pathway conserved from basal vertebrates to mammals
Ryczko, D., Cone, J. J., Alpert, M. H., Goetz, L., Auclair, F., Dubé, C., Parent, M., Roitman, M. F., Alford, S., & Dubuc, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600684113 · Cited by 101
“We used an adeno-associated virus-5 (AAV5) serotype, shown to infect cell bodies via retrograde transport from terminal fields (31).”
Distinct roles of TREM2 in central nervous system cancers and peripheral cancers
Zhong, J., Xing, X., Gao, Y., Pei, L., Lu, C., Sun, H., Lai, Y., Du, K., Xiao, F., Yang, Y., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.001 · Cited by 109
Xie, Y., Chan, A. W., McGirr, A., Xue, S., Xiao, D., Zeng, H., & Murphy, T. H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2744-15.2016 · Cited by 95
“2A) to exclusively express iGluSnFR in cortical neurons (Aschauer et al., 2013).”
BackgroundAntipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
Ibi, D., Revenga, M. D. L. F., Kezunovic, N., Muguruza, C., Saunders, J. M., Gaitonde, S. A., Moreno, J. L., Ijaz, M. K., Santosh, V., Kozlenkov, A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4616 · Cited by 109
Koike, H., Demars, M. P., Short, J. A., Nabel, E. M., Akbarian, S., Baxter, M. G., & Morishita, H. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.229 · Cited by 105
“…does not include the most anterior (AP+2.2mm) and posterior (AP− 0.1mm) portion of ACC, we expect the reported widespread transduction of AAV8 (Aschauer et al, 2013) allows the viral transduction to extend up to 500 μm from the injection sites close to the anterior and posterior boarder of…”
BackgroundInfluentialPfister, E. L., DiNardo, N., Mondo, E., Borel, F., Conroy, F., Fraser, C., Gernoux, G., Han, X., Hu, D., Johnson, E., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.199 · Cited by 95
Ochaba, J., Monteys, A. M., O’Rourke, J. G., Reidling, J. C., Steffan, J. S., Davidson, B. L., & Thompson, L. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.016 · Cited by 94
“Consistent with other studies (Aschauer et al., 2013; Harper et al., 2005; McBride et al., 2008), AAV2/1 and 2/2 viral transduction was neuronal as demonstrated by bIII-tubulin/eGFP co-localization and lack of GFP expression in microglia or astrocytes, as measured by Iba1 or GFAP co-staining (Figures 1A and 1B).”
Rapid Molecular Profiling of Defined Cell Types Using Viral TRAP
Nectow, A. R., Moya, M. V., Ekstrand, M. I., Mousa, A., McGuire, K. L., Sferrazza, C. E., Field, B. C., Rabinowitz, G. S., Sawicka, K., Liang, Y., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.048 · Cited by 92
“We created lists of ‘‘bacTRAP-specific’’ and ‘‘vTRAP-specific’’ genes, defined as the union of those differentially expressed between bacTRAP and vTRAP AAV9 IP samples and enriched in the IP over input for each approach (Figure S6A).”
MethodInfluentialNew Developments in Genetic rat models of Parkinson's Disease
Creed, R. B., & Goldberg, M. S. (2018) · Movement Disorders · doi:10.1002/mds.27296 · Cited by 102
“Viral gene expression can be targeted to specific subsets of cells using cell-type specific promoters and viral capsid proteins with different tropism and spreading properties.(94,136) The increasing number cell-”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“rAAV DNA carrier systems have been successfully used because they have a plethora of advantages: (1) They express the transgene within days or weeks and can reach full expression levels after 4–6 weeks in vivo [20,21].”
BackgroundGene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
Martier, R., & Konstantinova, P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580179 · Cited by 65
Thompson, N., Mastitskaya, S., & Holder, D. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.108325 · Cited by 92
Adekunbi, D. A., Li, X. F., Lass, G., Shetty, K., Adegoke, O. A., Yeo, S. H., Colledge, W. H., Lightman, S. L., & O'Byrne, K. T. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12572 · Cited by 87
Xhima, K., Nabbouh, F., Hynynen, K., Aubert, I., & Tandon, A. (2018) · Movement Disorders · doi:10.1002/mds.101 · Cited by 89
“The overall extent of the α-syn knockdown varied depending on the brain region, as transgene expression is influenced by local differences in transduction efficiency, cell-specific tropism, and the ratio of cell soma to axons.(99) Transduction efficiency was consistent with our previous reports,(48,51) and the graded…”
ResultSuper-resolution imaging of nuclear import of adeno-associated virus in live cells
Kelich, J. M., Ma, J., Dong, B., Wang, Q., Chin, M., Magura, C. M., Xiao, W., & Yang, W. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.47 · Cited by 78
Poststroke delivery of MANF promotes functional recovery in rats
Mätlik, K., Anttila, J. E., Tseng, K.-Y., Smolander, O., Pakarinen, E., Lehtonen, L. E., Abo‐Ramadan, U., Lindholm, P., Zheng, C., Harvey, B. K., et al. (2018) · Science Advances · doi:10.1126/sciadv.aap8957 · Cited by 83
Photo-activatable Cre recombinase regulates gene expression in vivo
Schindler, S. E., McCall, J. G., Yan, P., Hyrc, K. L., Li, M., Tucker, C. L., Lee, J., Bruchas, M. R., & Diamond, M. I. (2015) · Scientific Reports · doi:10.1038/srep13627 · Cited by 82
Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Kanaan, N. M., Sellnow, R. C., Boye, S. L., Coberly, B., Bennett, A., Agbandje-McKenna, M., Sortwell, C. E., Hauswirth, W. W., Boye, S. E., & Manfredsson, F. P. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.011 · Cited by 72
“HSPG Binding Restricts Tropism to Neuronal Cells Following intraparenchymal delivery, AAV primarily infects neurons; however, a small number of astrocytes and oligodendrocytes are also transduced.(24,29,30,44) In contrast, microglia have proven to be refractory to AAV transduction.”
BackgroundrAAV-compatible MiniPromoters for restricted expression in the brain and eye
de Leeuw, C. N., Korecki, A. J., Berry, G. E., Hickmott, J. W., Lam, S. L., Lengyell, T. C., Bonaguro, R. J., Borretta, L. J., Chopra, V., Chou, A. Y., et al. (2016) · Molecular Brain · doi:10.1186/s13041-016-0232-4 · Cited by 76
“After an initial wide survey of methodologies, we focused on neo-natal intravenous delivery of singlestranded rAAV in AAV9, due to its excellent capability to transduce a variety of CNS cell types in our hands and as described in the literature [27, 40, 41].”
MethodProspects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy
Domanskyi, A., Saarma, M., & Airavaara, M. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.065 · Cited by 75
“…81 and current clinical trials (Table 2) have used AAV2 as a vector for gene therapy, whereas studies indicate that AAV5 is more effective in transducing mouse and primate neurons 82,83 ; thus, choosing nonoptimal vector might have contributed to the failure of some initial clinical trials.”
A Multisensory Network for Olfactory Processing
Maier, J. X., Blankenship, M. L., Li, J. X., & Katz, D. B. (2015) · Current Biology · doi:10.1016/j.cub.2015.08.060 · Cited by 83
“AAV serotype 9 is known to spread well across the tissue and infect all cell types [55].”
Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells
Blessing, D., Vachey, G., Pythoud, C., Rey, M., Padrun, V., Wurm, F. M., Schneider, B. L., & Déglon, N. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.004 · Cited by 70
Manini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 82
“Compared to double stranded (ds) and single stranded (ss) AAV, the efficiency of cell transduction of scAAV vectors was significantly higher (66, 67), mainly due to the ability of scAAV to circumvent the step of second strand DNA synthesis mediated by the host cell (68).”
BackgroundBosch, M. E., Aldrich, A., Fallet, R., Odvody, J., Burkovetskaya, M., Schuberth, K., Fitzgerald, J. A., Foust, K. D., & Kielian, T. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1635-16.2016 · Cited by 69
“GFP expression was undetectable in microglia (data not shown), in agreement with previous reports showing that microglia are not permissive to AAV9-mediated transduction (Foust et al., 2009; Aschauer et al., 2013).”
ResultFang, J., Yuan, Q., Du, Z., Zhang, Q., Yang, L., Wang, M., Yang, W., Yuan, C., Yu, J., Wu, G., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.04.014 · Cited by 75
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
“This provides a range for the transduction efficiency which is in approximately the same range reported by other studies using different promoters [77,88].”
ResultWeiss, A. R., Liguore, W. A., Domire, J. S., Button, D. A., & McBride, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63559-7 · Cited by 69
“retro-eGFP transduced significantly more cells than AAV2-eGFP in all of the extra-striatal ROIs: AMY (t(2) = 82.”
BackgroundInfluentialBelur, L. R., Temme, A., Podetz-Pedersen, K. M., Riedl, M., Vulchanova, L., Robinson, N., Hanson, L. R., Kozarsky, K. F., Orchard, P. J., Frey, W. H., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.187 · Cited by 67
Prospects for mTOR-mediated functional repair after central nervous system trauma
Berry, M., Ahmed, Z., Morgan-Warren, P. J., Fulton, D. J., & Logan, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.002 · Cited by 71
“Thy1 for RGC), AAV vector neurotropism is age-dependent and not absolute (Harvey et al., 2002; Aschauer et al., 2013; Gholizadeh et al., 2013) and may lead to potentially deleterious side effects in nontargeted cells.”
BackgroundInteractions between respiratory oscillators in adult rats
Huckstepp, R. T. R., Henderson, L. E., Cardoza, K. P., & Feldman, J. L. (2016) · eLife · doi:10.7554/elife.14203 · Cited by 76
Autism spectrum disorder: prospects for treatment using gene therapy
Benger, M., Kinali, M., & Mazarakis, N. (2018) · Molecular Autism · doi:10.1186/s13229-018-0222-8 · Cited by 63
“AAV9 is particularly neurotropic [66, 67]) and/or promoter [68].”
BackgroundImaging neuromodulators with high spatiotemporal resolution using genetically encoded indicators
Patriarchi, T., Cho, J. R., Merten, K., Marley, A., Broussard, G. J., Liang, R., Williams, J., Nimmerjahn, A., von Zastrow, M., Gradinaru, V., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0239-2 · Cited by 66
Hwang, I., Kim, B.-S., Lee, H. Y., Cho, S. W., Lee, S. E., & Ahn, J. (2023) · Autophagy · doi:10.1080/15548627.2023.2259215 · Cited by 69
“This timing of viral injection enables AAV2 expression from day 1 after IR injury [28,29].”
BackgroundBehavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats
Marchant, N. J., Ramsey, L. A., Bossert, J. M., Harvey, B. K., Hope, B. T., Kaganovsky, K., Adhikary, S., Prisinzano, T. E., Vardy, E., Roth, B. L., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.149 · Cited by 75
“Aschauer et al (2013) provided evidence for complete overlap between neurons that were retrograde labeled with AAV and traditional retrograde tracers (cholera toxin b subunit: CTb); however, the total number of AAV-labeled neurons was lower than CTb labeled.”
BackgroundStandard screening methods underreport AAV-mediated transduction and gene editing
Lang, J. F., Toulmin, S. A., Brida, K. L., Eisenlohr, L. C., & Davidson, B. L. (2019) · Nature Communications · doi:10.1038/s41467-019-11321-7 · Cited by 67
Tiling and somatotopic alignment of mammalian low-threshold mechanoreceptors
Kuehn, E. D., Meltzer, S., Abraira, V. E., Ho, C.-Y., & Ginty, D. D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901378116 · Cited by 61
Mukherjee, N., Wachutka, J., & Katz, D. B. (2019) · eLife · doi:10.7554/elife.45968 · Cited by 65
Gant, J. C., Chen, K.-C., Kadish, I., Blalock, E. M., Thibault, O., Porter, N. M., & Landfield, P. W. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1248-15.2015 · Cited by 60
“These serotypes have been shown to exhibit high transduction efficiency in principal neurons of the brain (Broekman et al., 2006; Aschauer et al., 2013; Bosch et al., 2014), and in our studies all three serotypes showed good in vivo transduction of hippocampal pyramidal neurons in adult rats 4 – 6 weeks after microinj…”
BackgroundBatra, R., & Lee, C. W. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00196 · Cited by 65
“On the other hand, G4C2-repeat RNA expression in the AAV-G4C2-66 mice is dictated by the neuronal tropism of the AAV9 capsid, efficient delivery of viral vector by CSF flow with P0 injection and strong constitutive activity of the CBA promoter (Aschauer et al., 2013; Ayers et al., 2015).”
BackgroundA comprehensive atlas of AAV tropism in the mouse
Walkey, C. J., Snow, K. J., Bulcha, J., Cox, A. R., Martinez, A. E., Ljungberg, M. C., Lanza, D. G., Giorgi, M. D., Chuecos, M. A., Alves‐Bezerra, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.041 · Cited by 68
Molecular approaches for manipulating astrocytic signaling in vivo
Xie, A. X., Petravicz, J., & McCarthy, K. D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00144 · Cited by 55
“Several AAV serotypes show tropism toward astrocytes, including AAV 2/5 and AAV 8 (Koerber et al., 2009; Aschauer et al., 2013; Petrosyan et al., 2014).”
BackgroundInfluentialHashimoto, M., Yamanaka, A., Kato, S., Tanifuji, M., Kobayashi, K., & Yaginuma, H. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00006 · Cited by 66
“Each viral vector has a different viral tropism and efficiency of gene transfer (e.g., AAV vectors; Aschauer et al., 2013; Murlidharan et al., 2014).”
BackgroundNair, R. R., Blankvoort, S., Lagartos, M. J., & Kentros, C. (2020) · iScience · doi:10.1016/j.isci.2020.100888 · Cited by 55
Efficacy of gene delivery to the brain using AAV and ultrasound depends on serotypes and brain areas
Kofoed, R. H., Dibia, C. L., Noseworthy, K., Xhima, K., Vacaresse, N., Hynynen, K., & Aubert, I. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.048 · Cited by 67
Gérard, C., Xiao, X., Filali, M., Coulombe, Z., Arsenault, M., Couët, J., Li, J., Drolet, M., Chapdelaine, P., Chikh, A., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.44 · Cited by 67
Martier, R., Liefhebber, J., Miniarikova, J., van der Zon, T., Snapper, J., Kolder, I., Petry, H., van Deventer, S., Evers, M., & Konstantinova, P. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.01.010 · Cited by 53
“Furthermore, intrastriatal injections of AAV5 have been shown to distribute via axons through anterograde and/or retrograde transport and resulted in the transduction of different types of neurons, astrocytes, microglia, and oligodendrocytes.(70,71) Thus, a local delivery to the brain parenchyma is promising in patien…”
BackgroundStrobel, B., Zuckschwerdt, K., Zimmermann, G., Mayer, C., Eytner, R., Rechtsteiner, P., Kreuz, S., & Lamla, T. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.228 · Cited by 58
“In addition to the necessity for easy-to-produce and high-quality vectors during the development of novel gene therapies, AAV vectors are also required for their ever increasing application as a tool in basic and drug discovery research, for instance target validation and disease modeling.(2,3) Two important aspects t…”
BackgroundSelf-citationOkada, Y., Hosoi, N., Matsuzaki, Y., Fukai, Y., Hiraga, A., Nakai, J., Nitta, K., Shinohara, Y., Konno, A., & Hirai, H. (2022) · Communications Biology · doi:10.1038/s42003-022-04200-3 · Cited by 58
Scheyltjens, I., Laramée, M., den Haute, C. V., Gijsbers, R., Debyser, Z., Baekelandt, V., Vreysen, S., & Arckens, L. (2015) · The Journal of Comparative Neurology · doi:10.1002/cne.23819 · Cited by 67
“…vectors result in both anterograde and retrograde labeling in the dLGN, whereas CaMKIIa 0.4 vectors only result in anterograde labeling, except for rAAV2/5, which can again be in accordance with its strong retrograde labeling abilities (Van der Perren et al., 2011; Aschauer et al., 2013).”
BackgroundResultInfluentialA MicroRNA-Based Gene-Targeting Tool for Virally Labeling Interneurons in the Rodent Cortex
Keaveney, M. K., Tseng, H.-A., Ta, T. L., Gritton, H. J., Man, H.-Y., & Han, X. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.049 · Cited by 55
“Recently, a systematic comparison of AAV serotypes 1, 2, 5, 6, 8, and 9 in the mouse brain demonstrated that AAV serotype 9 is most efficient for transducing cortical neurons, with slight tropism toward cortical inhibitory neurons (Aschauer et al., 2013).”
BackgroundRadhiyanti, P. T., Konno, A., Matsuzaki, Y., & Hirai, H. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135956 · Cited by 60
Wouterlood, F. G., Bloem, B., Mansvelder, H. D., Luchicchi, A., & Deisseroth, K. A. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.07.021 · Cited by 60
Large-Scale Fluorescence Calcium-Imaging Methods for Studies of Long-Term Memory in Behaving Mammals
Jercog, P. E., Rogerson, T., & Schnitzer, M. J. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021824 · Cited by 58
“A key consideration with the use of an AAV concerns the viral serotype, because distinct serotypes of AAV enter different neuron types to varying degrees (Aschauer et al. 2013).”
BackgroundDestination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55
“Similarly, variations in route of administration (Gray et al. 2011; Aschauer et al. 2013) and species tested (Bevan et al.”
InfluentialA Comparative Analysis of Constitutive Promoters Located in Adeno-Associated Viral Vectors
Damdindorj, L., Karnan, S., Ota, A., Hossain, E., Konishi, Y., Hosokawa, Y., & Konishi, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106472 · Cited by 62
“However, gene expression driven by respective promoters in these cell lines may vary depending on the serotype of AAV vectors employed, in view of previous studies indicating distinct gene transduction abilities and tropisms of AAV vectors based on different serotypes [49,50].”
BackgroundDemars, M. P., & Morishita, H. (2014) · Molecular Brain · doi:10.1186/s13041-014-0075-9 · Cited by 51
“Specifically, we utilized SST-cre mice and cre-dependent retrograde viral GFP labeling using AAV5-DIO-EGFP [42] and performed DISH with probes designed to recognize Lypd6 and GFP mRNA.”
Metadata
- Authors
- Aschauer, D. F., Kreuz, S., & Rumpel, S.
- Affiliations
- Research Institute of Molecular Pathology (AT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Rumpel, Simon
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-27
- Volume
- 8
- Issue
- 9
- Pages
- e76310
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3785459
- OpenAlex
- W2015741711
- Cited by
- 522
- References
- 68
- Citations by year
- 2026: 26 · 2025: 31 · 2024: 47 · 2023: 44 · 2022: 40 · 2021: 49 · 2020: 44 · 2019: 57 · 2018: 45 · 2017: 42 · 2016: 42 · 2015: 34 · 2014: 20 · 2013: 1
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, AAV serotypes, AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, transduction efficiency, axonal transport, retrograde transport, self-complementary AAV, gene delivery to the brain, striatum, hippocampus, neocortex, astrocytes, cortical neurons, microglia, oligodendrocytes, entorhinal cortex, dentate gyrus, reporter gene expression
- MeSH terms
- Dependovirus, Analysis of Variance, Animals, Axonal Transport, Brain, Cloning, Molecular, Gene Expression Regulation, Genetic Vectors, Microscopy, Fluorescence, Organ Specificity, Transduction, Genetic, Gene Transfer Techniques, Transgenes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.